Monday, 25 Sep 2017

You are here

BUILD Study - Baricitinib Shows Rapid Efficacy and X-ray Protection

Baricitinib is an oral, small molecule, once-daily DMARD, that specifically inhibits Janus kinase 1 and 2 and is being developed for use in rheumatoid arthritis. With much of the developmental clinical trials completed, the drug is slated for review and potential approval near the end of the year. 

The baricitinib pivotal studies include the BEGIN study (early RA; MTX naive), BEACON study (TNF incomplete responders [IR]), BEAM study (MTX-IR) and the BUILD study (DMARD-IR). The latter study results were just published in ARD.

The BUILD study was a phase III, 24-week study of 684 RA patients who had failed at least one DMARD. Patients had to be biologic naive and were randomized to receive either placebo or baricitinib (2 or 4 mg) once daily.  The endpoint was the ACR20 response at week 12 and X-ray (TSS) scores at week 24.

Baricitinib showed a significantly greater ACR20 response at week 12 (4 mg 62% vs placebo 39%, p≤0.001).

Not surprisingly, all secondary endpoints were significantly greater with both baricitinib doses. This included radiographic assessments that showed less structural joint damage at week 24 was reduced with baricitinib versus placebo.

Baricitinib was associated with a decrease in neutrophils and increases in low-density and high-density lipoprotein. There were no differences in SAEs or SIEs in treatment groups. There was one case of tuberculosis and one patient with a non-melanoma skin cancer on baricitinib 4 mg.

The 4 mg baricitinib group yielded the most robust results.  It is unclear from data yet reported what the best or approved dose will be.

Disclosures: 
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

Rituximab Efficacy in IgG4 Related Disease

PLOS reports  greater than 90% efficacy when rituximab (RTX) is used to treat patients with IgG4-related disease (IgG4-RD). 

Jak Inhibition May Ameliorate Pruritus

Interleukin-4 has been shown to activate sensory neurons involved in pruritus, and that inhibition of IL-4 with Jak inhibition significantly alleviates itching.

Biologic Use in Adult-Onset Still's Disease

 Adult-onset Still's disease (AOSD) is the adult continum of systemic-onset juvenile idiopathic arthritis (SoJIA). Treatment of this febrile polyarticular systemic disorder can be complex, but has been relieved by several specific biologic therapies.

New Recommendations on Biosimilar Use

The introduction of a growing number of biosimilars into the market poses a substantial change in cost of care for patients with inflammatory rheumatologic disorders.  

Turnabout for Baricitinib

Eli Lilly and Company and Incyte Corporation announced today that, after discussions with the U.S. Food and Drug Administration in late August 2017, Lilly will resubmit a revised New Drug Application for baricitinib before the end of January 2018. The resubmission package will include new safety and efficacy data.